Evidence map›Paper›PMID 41888694›Full record

ArticleBMC infectious diseases2026

A machine learning-based prediction model for treatment efficacy in smear and/or chest X-ray positive tuberculosis patients.

Xiaohua Cui, Wei Fu, Xuan Wu, Zhe Peng, Wentao Wu

Abstract read
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaohua Cui *Department of Tuberculosis, Henan Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, 450008, China.
Wei Fu *Department of Tuberculosis, Henan Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, 450008, China.
Xuan WuDepartment of Tuberculosis, Henan Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, 450008, China.
Zhe PengDepartment of Tuberculosis, Henan Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, 450008, China.
Wentao WuDepartment of Tuberculosis, Henan Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, 450008, China. 19313483976@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a machine learning (ML)-based prediction model for tuberculosis (TB) treatment failure, and evaluate the predictive performance and clinical utility.

methodsPatients were randomly allocated to a training set and a validation set in a 7:3 ratio. Data collected included demographic characteristics, clinical features, and laboratory parameters. Univariate analysis and binary logistic regression were applied to the training set to identify factors associated with treatment outcome. Based on common predictive modeling standards, an AUC > 0.8 was considered good, and > 0.9 was considered excellent. Three prediction models—Random Forest (RF), Support Vector Machine (SVM), and K-Nearest Neighbors (KNN)—were constructed. Model performance was evaluated based on accuracy, precision, recall, F1-score, and the area under the receiver operating characteristic curve (AUC).

resultsAmong 541 enrolled patients, 133 (24.58%) experienced treatment failure (92 [24.27%] in the training set and 41 [25.31%] in the validation set).Cavitation, diabetes comorbidity, radiographic disease extent, TB type (pulmonary vs. extrapulmonary), lymphocyte percentage (LYMPH%), and serum albumin (ALB) level were identified as significant predictors of treatment outcome (P < 0.05). The RF, SVM, and KNN models achieved AUC values of 0.783, 0.707, and 0.668, respectively.

conclusionThe ML-based prediction model shows fair to good predictive performance (AUC up to 0.783), suggesting potential clinical utility with further validation. This model may assist in early risk stratification and support individualized treatment planning for tuberculosis patients. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Antitubercular AgentsMachine LearningTuberculosisTuberculosis, PulmonaryAdultClassification AlgorithmsFemaleHumansLogistic ModelsMaleMiddle AgedPrediction AlgorithmsPredictive Learning ModelsRadiography, ThoracicRandom ForestROC CurveAntitubercular AgentsLogistic regressionMachine learningPrediction modelTreatment outcomeTuberculosis

Identifiers

PMID41888694
PMCPMC13147690

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.